Apotex, a Canadian manufacturing company of pharmaceuticals, has voluntarily recalled the drug Apo-Clindamycin 150mg and 300mg capsules, an antibiotic used to treat certain types of infections.
The Ministry of Health, through the Barbados Drug Service (BDS), has already returned several batches of the Apo-Clindamycin 150mg and 300mg capsules to the local agent and is working with that distributor to ensure all identified batches of the antibiotic preparation that were sold in Barbados are returned.
Speaking about the issue, Director of the BDS, Maryam Hinds said: “The Barbados Drug Service has been advised that there is the possibility of cross-contamination of the Apo-Clindamycin 150mg and 300mg capsules.
The potential for serious adverse health consequences is remote, but Apotex is taking every precautionary measure.”
Apotex recently recalled another drug, Apo-Amoxi-Clav 125 mg/31.25mg per five ml; and the Apo-Amoxi-Clav 250mg/62.25 per five ml from other markets. However, none of the affected batches has reached Barbados.